
UCB is a global biopharmaceutical company that was founded in 1996 by Pierre and Jean-Christophe Tellier. UCB is headquartered in Brussels, Belgium.
The company has a strong presence in over 40 countries worldwide, with a diverse portfolio of products that include medicines for immunology, neurology, and oncology. UCB's products are used to treat a range of conditions, from multiple sclerosis and rheumatoid arthritis to epilepsy and cancer.
UCB has a significant research and development program, with a focus on innovative treatments for complex diseases. The company has a strong commitment to research and development, investing over 20% of its revenue in R&D each year.
UCB's business operations are supported by a global network of manufacturing facilities, research centers, and distribution partners.
Industry Data and Insights
UCB's investment in the US has been significant, with a $5 billion investment aimed at creating a shorter and more resilient supply chain for its U.S. customers.
The company has been operating in the US since 1994, with roughly 2,000 current employees. UCB's U.S. headquarters is based in Atlanta, and the company operates three research and development centers across the country in Seattle, Boston, and Durham, North Carolina.
You might like: U. S. Steel Košice, S.r.o.
UCB has invested $4.5 billion in the country since 2017, gaining 15 Food and Drug Administration approvals over the past eight years. This investment has helped the company grow its revenue, which hit 6.15 billion euros in fiscal year 2024, up 17% from the previous year.
The company's growth strategy includes expanding its biologics manufacturing footprint and growing its contract drug manufacturing partnerships. UCB has been in a strategic growth mode in recent months, bringing five new drugs to market and studying nine new drugs in its pipeline this year.
Here are some key statistics about UCB's US investments:
- UCB has invested $4.5 billion in the US since 2017.
- The company has gained 15 Food and Drug Administration approvals over the past eight years.
- UCB's revenue hit 6.15 billion euros in fiscal year 2024, up 17% from the previous year.
Clinical Trials and Research
UCB's approach to clinical trials is a crucial aspect of their business. They determine their go-to-market proposition to gain insight into the company's clinical operations.
UCB focuses on recruitment and trial strategy to ensure the success of their clinical trials. This involves careful planning and execution to meet their goals.
To gain a deeper understanding of UCB's clinical trials, it's essential to look at their operations, recruitment, and trial strategy.
If this caught your attention, see: Global Strategy Group
Clinical Trials
Clinical trials are a crucial step in bringing new treatments to patients. UCB SA, a biopharmaceutical company, conducts clinical trials to test the safety and efficacy of its products.
UCB SA's clinical operations involve multiple stages, including planning, execution, and monitoring. The company's recruitment strategy is designed to attract the right participants for each trial.
Clinical trials involve determining a company's go-to-market proposition, which is essentially its unique selling point. This involves gaining insight into the company's clinical operations, recruitment, and trial strategy.
UCB SA's trial strategy likely involves identifying the most promising candidates and designing trials that will provide the most reliable data. This requires careful planning and execution to ensure the trials are conducted efficiently and effectively.
Here's an interesting read: Astra-Unceta Y Cia SA
470+
Understanding the commercialized product portfolio of UCB SA is crucial for staying ahead of the market, with over 470+ products developed and launched by the company.
UCB SA's extensive portfolio reflects its commitment to innovation and research, with a wide range of products addressing various therapeutic areas.
You might enjoy: Bnp Paribas Fortis Sa
The company's commercialized product portfolio includes multiple products, each with its own unique features and benefits.
UCB SA's focus on commercialization has enabled the company to reach a large customer base and establish a strong presence in the market.
With a diverse portfolio of products, UCB SA is well-positioned to adapt to changing market trends and customer needs.
See what others are reading: Malik V Bank of Credit and Commerce International SA
Investigations and Partnerships
UCB is a global biopharmaceutical company that collaborates with various partners to drive innovation and improve patient outcomes.
The company has a strong track record of partnerships, with collaborations in place with over 40 pharmaceutical companies worldwide.
One notable example is UCB's partnership with the National Eczema Association, which aims to improve the lives of people with eczema through research and education.
Investigators
Reviewing investigator profiles can be a game-changer for your work. You can find information on trial contacts across UCB SA, including performance indicators like the number of completed trials.
Performance indicators like the number of completed trials can give you a clear picture of an investigator's capabilities. This information can also be linked to attributes such as rehiring statistics.
UCB SA's investigators have a proven track record of delivering successful trials. Their expertise and efficiency make them a valuable asset to any research project.
For your interest: Holley Performance Products
How Sa Works

UCB SA is a global biopharmaceutical company with a strong focus on innovative medicines. They have a robust R&D pipeline, with a focus on biologics and monoclonal antibodies.
As of Q2 2023, UCB's R&D investment was approximately 29.2% of its total revenue, underscoring their commitment to innovation. This significant investment in R&D has helped the company achieve notable growth.
In 2022, UCB reported total revenue of €5.15 billion, a notable increase from €4.63 billion in 2021, reflecting a growth of approximately 11.1%. This growth is a testament to the company's successful strategies.
UCB's key products include Vimpat (used for epilepsy), Cimzia (for autoimmune diseases), and even the recently launched therapies in 2023 aimed at treating severe chronic diseases. Sales from these products have contributed significantly to the company's revenue.
Here's a breakdown of UCB's revenue distribution by product:
UCB maintains a strong balance sheet, with a total asset value of €8.7 billion as of Q2 2023, and a net debt of approximately €900 million. The company's debt-to-equity ratio is about 0.5, indicating a solid financial position.
Business Operations
UCB's business operations are built around its commitment to research and development, with a significant investment of around €1.3 billion in 2022, accounting for approximately 24.5% of total revenues.
The company's strategy emphasizes the development of innovative medicines in areas of neurology and immunology, with a focus on products like Vimpat, Keppra, Briviact, and Cimzia. These products generated a significant portion of the company's revenue in 2022, with Vimpat accounting for 26.4% of total revenue.
UCB's revenue streams are diversified across multiple regions, with Europe accounting for 50.9% of total revenue in 2022, followed by North America at 34.0% and the Rest of the World at 15.1%.
The company's collaboration with Amgen in 2022 resulted in an upfront payment of €200 million and potential milestone payments tied to product development, further diversifying its revenue streams.
How SA Generates Revenue
UCB SA generates revenue through its innovative medicines in neurology and immunology. The company's major revenue-generating products include Vimpat, Keppra, Briviact, and Cimzia.
In 2022, UCB reported total revenues of approximately €5.3 billion, reflecting a year-over-year growth driven by strong product performance. This growth was primarily driven by the success of its major products.
Vimpat, an epileptic drug, generated €1.4 billion in revenue, accounting for 26.4% of UCB's total revenue in 2022. Keppra, an anti-epileptic agent, generated €1.2 billion in revenue, accounting for 22.6% of UCB's total revenue in 2022.
UCB's revenue breakdown by product line in 2022 was as follows:
The company's strategy emphasizes investment in research and development (R&D), which totaled around €1.3 billion in 2022, accounting for approximately 24.5% of total revenues. This supports the ongoing development of new treatments, particularly in neurology and immunology.
IT Services Contracts
When managing IT services contracts, it's essential to have a clear understanding of your options and the market.
Improving competitive bidding can be achieved by gaining insights into publicly disclosed IT services contracts.
For companies like UCB SA, this means having access to information on IT outsourcing, business process outsourcing, systems integration, and consulting contracts.
This knowledge can help businesses make informed decisions and negotiate better deals.
UCB SA's publicly disclosed IT services contracts can provide valuable insights into market trends and competitor activity.
By leveraging this information, companies can refine their bidding strategies and increase their chances of securing contracts.
If this caught your attention, see: Dagbladet Information
Ownership and Stock Information
UCB SA, a biopharmaceutical company based in Brussels, Belgium, has a diverse ownership structure. The company is owned by a mix of institutional investors, private individuals, and company management.
Institutional investors hold a significant stake in UCB SA, with a total of 65.3% of the company's shares. This includes major institutional shareholders such as BlackRock, Inc., The Vanguard Group, Inc., Fidelity Management & Research Company, and BNP Paribas Asset Management.
The company's management also holds a notable stake in UCB SA, with CEO Dr. Jean-Christophe Tellier owning approximately 0.8% of the company's shares, and other executive members collectively holding around 1.0%.
UCB SA's total number of outstanding shares is approximately 189 million, and the company's market capitalization as of October 2023 stands at around €22.7 billion.
Here is a breakdown of the company's ownership structure:
The company's stock is listed on the Euronext Brussels exchange under the ticker symbol UCB.
Frequently Asked Questions
Is UCB a good company to work for?
UCB has a 4.0/5 rating based on over 1,300 employee reviews, with 81% recommending it to a friend. Employees have a positive outlook on the business, making it a company worth considering for a career.
Featured Images: pexels.com


